Is COPD a Risk Factor for Cardiovascular Disease?

Overview

Patients with chronic obstructive pulmonary disease suffer from significant cardiovascular morbidity and mortality. This study wants to determine whether chronic obstructive pulmonary disease might be a risk factor for coronary atherosclerosis and other cardiac markers independent of conventional cardiovascular risk factors. The study is designed as a retrospective matched case-control study with follow-up via telephone interview.

Full Title of Study: “Is Chronic Obstructive Pulmonary Disease a Risk Factor for Cardiovascular Disease?”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: December 2014

Detailed Description

Patients with chronic obstructive pulmonary disease (COPD) suffer from significant cardiovascular morbidity and mortality. Coronary artery disease has often been linked causally to COPD, but the exact pathophysiological mechanisms underpinning this association remain speculative. A retrospective case-control study matching COPD patients and controls one to one for smoking history and conventional cardiovascular risk factors will be performed to study the association between COPD and cardiovascular outcomes. Filling in this knowledge gap may contribute to the understanding of the interplay between COPD and cardiovascular disease.

The objective of this retrospective case-control study is to determine whether COPD might be a risk factor for coronary atherosclerosis, impaired left ventricular ejection fraction, and major adverse cardiovascular events independent of conventional cardiovascular risk factors.

Arms, Groups and Cohorts

  • Chronic obstructive pulmonary disease
    • Approximately 100 participants with documented chronic obstructive pulmonary disease (post-bronchodilator Forced expiratory volume in 1 second (FEV1)/Forced vital capacity (FVC) < 0.7).
  • Control
    • Approximately 100 participants with exclusion of chronic obstructive pulmonary disease (post-bronchodilator Forced expiratory volume in 1 second (FEV1)/Forced vital capacity (FVC) > 0.7).

Clinical Trial Outcome Measures

Primary Measures

  • Coronary calcium score in cardiac computed tomography
    • Time Frame: Up to one month
    • Retrospective assessment of SPECT-CT imaging data at the University Hospital Zurich.

Secondary Measures

  • Left ventricular ejection fraction in single-photon emission computed tomography
    • Time Frame: Up to one month
    • Retrospective assessment of SPECT-CT imaging data at the University Hospital Zurich.
  • Major adverse cardiovascular events
    • Time Frame: Up to three months
    • Follow-up via telephone interview for major adverse cardiovascular events.

Participating in This Clinical Trial

Inclusion Criteria

  • SPECT-CT imaging due to preoperative assessment between 01.01.2007 and 31.07.2013.
  • Coronary artery calcium score and left ventricular ejection fraction data available.
  • History of smoking (smoker or ex-smoker).
  • COPD group: Documented chronic obstructive pulmonary disease (post-bronchodilator FEV1/FVC < 0.7).
  • Control group: Exclusion of chronic obstructive pulmonary disease (post-bronchodilator FEV1/FVC > 0.7).

Exclusion Criteria

  • Known coronary artery disease or coronary symptoms (angina pectoris) at the time of the SPECT-CT investigation.
  • Known congenital or structural heart disease.
  • Previous heart transplantation.

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Zurich
  • Collaborator
    • University Hospital, Z├╝rich
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Malcolm Kohler, MD, Prof, Principal Investigator, University of Zurich

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.